Anthera will conduct $8 million registered direct offering of shares

Offering sells 3,216,646 common shares to investors Zenyaku and Amgen

By Devika Patel

Knoxville, Tenn., Jan. 28 – Anthera Pharmaceuticals, Inc. negotiated an $8 million registered direct offering of stock on Jan. 27, according to an 8-K and prospectus supplement filed Wednesday with the Securities and Exchange Commission.

The company will sell 3,216,646 common shares. It will sell 2,795,895 shares to Zenyaku Kogyo Co., Ltd. at $2.50367 per share and 420,751 shares to Amgen Inc. at $2.3767 per share. The prices per share are 6.09% and 0.71% premiums to $2.36, the Jan. 26 closing share price.

Settlement is expected Jan. 28.

Proceeds will be used for general corporate purposes.

Anthera, based in Hayward, Calif., is a biopharmaceutical company.

Issuer:	Anthera Pharmaceuticals, Inc.
Issue:	Common stock
Amount:	$8 million
Shares:	3,216,646
Price:	$2.50367 (for 2,795,895 shares), $2.3767 (for 420,751 shares)
Warrants:	For 2,505,852 shares
Warrant expiration:	Five years
Warrant strike price:	$1.82
Investors:	Zenyaku Kogyo Co., Ltd. (for $7 million), Amgen Inc. (for $1 million)
Pricing date:	Jan. 27
Settlement date:	Jan. 28
Stock symbol:	Nasdaq: ANTH
Stock price:	$2.36 at close Jan. 26
Market capitalization:	$57.35 million

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.